Study Links VPS35 Mutations to Chemotherapy Resistance in Certain Cancers

Researchers at Mass General Brigham have identified mutations in the VPS35 gene that may contribute to resistance against certain chemotherapies. The study, published in *Nature*, examined a cellular pathway that utilizes reactive oxygen species (ROS) to destroy cancer cells. Findings indicate that alterations in VPS35 can disrupt this process, potentially allowing tumors to evade chemotherapy-induced cell death.

The research highlights the role of VPS35 as a critical component in the ROS-mediated cancer treatment pathway. By analyzing how these mutations interfere with chemotherapy’s effectiveness, scientists aim to better understand why some tumors resist treatment. These insights could assist in identifying resistant cancers and tailoring more effective therapeutic strategies for patients.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Breakthrough in Cancer Vaccine Development Enhances Effectiveness and Reach How the Brain Rewires Itself for Language Recovery After a Stroke Breakthrough in Skin Cancer Treatment: Promising Results from New Therapy Jazz Pharmaceuticals Announces $1 Billion Acquisition of Chimerix to Advance Brain Cancer Treatment

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後